Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | Zendy

Jennifer Hammond | Zendy; Heidi LeisterTebbe | Zendy; Annie Gardner | Zendy; Paula Abreu | Zendy; Weihang Bao | Zendy; Wayne Wisemandle | Zendy; MaryLynn Baniecki | Zendy; Victoria M. Hendrick | Zendy; Bharat Damle | Zendy; Jesus Abraham Simón Campos | Zendy; Rienk Pypstra | Zendy; James M. Rusnak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Author(s) -

Jennifer Hammond,

Heidi LeisterTebbe,

Annie Gardner,

Paula Abreu,

Weihang Bao,

Wayne Wisemandle,

MaryLynn Baniecki,

Victoria M. Hendrick,

Bharat Damle,

Jesus Abraham Simón Campos,

Rienk Pypstra,

James M. Rusnak

Publication year - 2022

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2118542

Subject(s) - covid-19 , coronavirus , protease inhibitor (pharmacology) , protease , coronavirus infections , in vitro , virology , betacoronavirus , medicine , biology , virus , viral load , enzyme , biochemistry , outbreak , disease , infectious disease (medical specialty) , antiretroviral therapy

Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research